.png){kind=icon}
.png){kind=icon}
Return
Therapeutic Efficacy of 7-Chloro-4-(phenylselanyl)quinoline against Oncological Pain Induced by Tumor Progression and Vincristine Treatment
.png){kind=icon}
OA
AI
K
V
B
T
F
J
M
R
D
N
N
R
J
P
V
M
E
DOI：10.1021/acsomega.5c11481.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cancer pain is a complex condition often worsened by tumor progression and chemotherapy-induced neuropathy. This study evaluated the therapeutic potential of 7-chloro-4-(phenylselanyl)quinoline (4-PSQ) in mice with Sarcoma 180 (S180)-induced cancer pain and vincristine (VCR)-induced peripheral neuropathy. Male mice were assigned to Control, S180, S180 + VCR, S180 + 4-PSQ, and S180 + VCR + 4-PSQ groups. S180 cells were injected intraplantarly on day 1; VCR was administered days 2–6, and 4-PSQ orally from days 8–17. Nociceptive behavior, tumor progression, and tissue biomarkers were assessed. S180 and VCR caused hyperalgesia, tumor edema, oxidative imbalance, and impaired Na+/K+/Mg2+-ATPase activities. 4-PSQ attenuated hyperalgesia, tumor growth, oxidative stress, and immune dysregulation, restoring ATPase activities. Histology confirmed a tumor mass and inflammatory infiltration. These results indicate that 4-PSQ exerts antinociceptive, antioxidant, and immunomodulatory effects, supporting its potential as an adjuvant therapy for cancer pain and chemotherapy-induced neuropathy.
Keywords:
Cancer
Immunology
Inflammation
Neurophysiology
Rodent models
Journal
IF:
4.3
Papers:
3.3W
Citations:
9.8W
Organization
Cited Papers